TPS CLIA is now ready for market introduction in China
Our partner ZECEN Biotech has now received the registration certificate from the Chinese registration authorities NMPA, which means that the product has received final approval for sales in China TPS CLIA will be available on the Chinese market at the beginning of next year. During next year, ZECEN Biotech is also expecting regulatory approval for TPS CLIA on Fosun Diagnostics fully automated CLIA platforms.
“AroCell is very pleased that the first project with ZECEN Biotech is completed, and that the product is ready to be launched on the Chinese market early next year. We are also looking forward to continuing our collaboration with ZECEN Biotech, to add the TPS CLIA on other CLIA platforms and expand collaboration into other tumor markers on their CLIA machines in the future” says Marie Torstensson, Chief Market and Sales Officer Laboratory Test.
ZECEN Biotech Co., Ltd., is a Chinese company that primarily specializes in providing total solutions for chemiluminescence immunoassay by developing, manufacturing, and marketing CLIA instruments and reagents. The company has research and development centers and a production base in Beijing, Shandong, and Jiangsu. ZECEN Biotech Co., Ltd., and collaborates with leading hospitals in China.
Fosun Diagnostics is a division within Shanghai Fosun Pharmaceutical (Group) Co Ltd, focusing on developing, manufacturing, and distributing in vitro diagnostics (IVD) products.